{"id":"who-recommended-periodic-presumptive-treatment","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbance"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL17","moleculeType":"Small molecule","molecularWeight":"305.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PPT is a preventive strategy that delivers therapeutic doses of antimalarials (typically sulfadoxine-pyrimethamine or artemisinin-based combinations) on a fixed schedule rather than waiting for confirmed infection. This approach reduces the burden of malaria parasites in the blood and tissues, preventing clinical disease and complications such as severe anemia and low birth weight in pregnant women. The strategy is particularly effective in areas of moderate to high malaria transmission.","oneSentence":"WHO-recommended periodic presumptive treatment (PPT) involves administering antimalarial drugs at regular intervals to pregnant women or other at-risk populations to prevent malaria infection regardless of parasitemia status.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:16:09.483Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria prevention in pregnant women in endemic areas"},{"name":"Malaria prevention in infants and children in endemic areas"}]},"trialDetails":[{"nctId":"NCT06468462","phase":"PHASE4","title":"Periodic Presumptive Treatment vs. doxyPEP for STI Control in Kenyan MSM","status":"RECRUITING","sponsor":"University of Washington","startDate":"2025-10-29","conditions":"Gonorrhea Male, Chlamydia (Male), Syphilis Male","enrollment":2900}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["WHO PPT"],"phase":"marketed","status":"active","brandName":"WHO-recommended periodic presumptive treatment","genericName":"WHO-recommended periodic presumptive treatment","companyName":"University of Washington","companyId":"university-of-washington","modality":"Small molecule","firstApprovalDate":"","aiSummary":"WHO-recommended periodic presumptive treatment (PPT) involves administering antimalarial drugs at regular intervals to pregnant women or other at-risk populations to prevent malaria infection regardless of parasitemia status. Used for Malaria prevention in pregnant women in endemic areas, Malaria prevention in infants and children in endemic areas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}